Chronic hepatitis B management
HBV chronic · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic hepatitis B virus infection (HBsAg positive over 6 months) requires staging of disease phase to decide on nucleos(t)ide antiviral therapy, with lifelong surveillance for cirrhosis and hepatocellular carcinoma. Treatment suppresses viral replication but rarely clears HBsAg.
Red flags
- Decompensation: ascites, encephalopathy, variceal bleeding
- Rapid ALT rise/flare
- New focal liver lesion on imaging
- Pregnancy with very high viral load (perinatal transmission risk)
- Hepatitis delta co-infection (accelerated fibrosis)
Assessment
Differential diagnosis
- Hepatitis B immune-tolerant phase
- HBeAg-positive or HBeAg-negative chronic hepatitis
- Inactive carrier (low replicative) state
- Hepatitis delta co-infection
- Other chronic liver disease (alcohol, NAFLD, hepatitis C)
Investigations
- HBsAg, HBeAg/anti-HBe, HBV DNA viral load
- ALT and liver function tests
- Hepatitis delta antibody, hepatitis C and HIV co-infection screen
- Liver fibrosis assessment (transient elastography or fibrosis score)
- Alpha-fetoprotein and liver ultrasound
- Renal function and phosphate (for tenofovir choice)
Management
- Confirm chronicity and determine disease phase using HBV DNA, HBeAg and ALT
- Assess fibrosis stage with elastography; identify cirrhosis
- Screen for hepatitis delta, C and HIV co-infection
- Treat all with cirrhosis, significant fibrosis, or active hepatitis meeting thresholds
- Start a high-barrier nucleos(t)ide analogue (tenofovir or entecavir)
- Vaccinate household/sexual contacts and against hepatitis A
- Give antiviral prophylaxis before immunosuppression/chemotherapy regardless of phase
- Monitor HBV DNA, ALT and renal function periodically
- Perform 6-monthly HCC surveillance ultrasound in cirrhosis and selected others
- Counsel on transmission, alcohol avoidance and adherence
- Continue therapy long-term; stopping only under specialist guidance
- Refer pregnant people with high viral load for third-trimester tenofovir
Drugs & doses
Tenofovir disoproxil 245 mg PO once daily
Tenofovir alafenamide 25 mg PO once daily (renal/bone concerns)
Entecavir 0.5 mg PO once daily (1 mg if lamivudine-experienced)
Peginterferon alfa-2a 180 microgram SC weekly for 48 weeks (selected cases)
Disposition
Hepatology/ID outpatient; admit if decompensated; lifelong surveillance.
Complications & pitfalls
- Cirrhosis and portal hypertension
- Hepatocellular carcinoma
- Hepatitis flare on antiviral withdrawal
- Reactivation during immunosuppression
- Perinatal/horizontal transmission
Exam pearls
- Tenofovir and entecavir have high resistance barriers; avoid lamivudine monotherapy
- Never stop antivirals abruptly in cirrhosis; flares can be fatal
- Always give prophylaxis before rituximab or chemotherapy in any HBsAg or anti-HBc positive patient
- Third-trimester tenofovir plus infant vaccine/immunoglobulin prevents vertical transmission
- HBsAg loss is the functional cure endpoint and is uncommon
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.